Ask ten cannabis consumers whether vaping is healthier than smoking and you’ll get ten confident answers, most of them based on vibes.
The actual research is more interesting than the folklore — broadly encouraging for vaporisers, but with a couple of genuine caveats that rarely make it into the conversation. Here’s what the science says, with links so you can check it yourself.
The problem was never the plant. It’s the fire.
When you spark a joint, the cherry burns at several hundred degrees Celsius. At those temperatures you’re not just liberating THC — you’re running an uncontrolled combustion reaction that produces tar, carbon monoxide and a long list of pyrolytic by-products.
This has been documented for decades. Back in 1988, Donald Tashkin’s group at UCLA published a study in the New England Journal of Medicine showing that, puff for puff, smoking cannabis deposited roughly three times more tar in the respiratory tract than tobacco, and produced substantially higher carboxyhaemoglobin levels — partly because of how we smoke it: bigger puffs, deeper inhalation, longer breath-holds, no filter.
Later chemical analyses confirmed the picture. Government researchers in Canada (Moir et al., 2008) ran cannabis and tobacco cigarettes through smoking machines and found that several toxicants — including hydrogen cyanide, nitrogen oxides and aromatic amines — appeared in cannabis smoke at concentrations three to five times higher than in tobacco smoke, with comparable levels of tar and particulate matter.
None of this means cannabis smoking is as dangerous as tobacco smoking — the epidemiology has never supported that leap, and long-term studies of cannabis-only smokers show far milder outcomes than tobacco. But “less harmful than cigarettes” is a low bar. Chronic bronchitis, cough, phlegm and wheeze are all well documented in regular smokers of the herb.
What vaporisation changes
A dry herb vaporiser sidesteps combustion entirely. Instead of burning the flower, it heats it to somewhere between roughly 160°C and 220°C — hot enough to boil cannabinoids and terpenes off into an inhalable vapour, but well below the temperature at which plant material ignites and the nasty chemistry begins.
The landmark clinical test of this idea came from Donald Abrams and colleagues at UCSF in 2007. Their pilot study in Clinical Pharmacology & Therapeutics had volunteers either smoke cannabis or inhale it through a Volcano vaporiser across six days.
Blood THC levels were essentially equivalent between the two methods — but carbon monoxide exposure dropped dramatically with vaporisation, and participants overwhelmingly preferred it. In plain terms: same cannabinoids, a fraction of the combustion gases.
What happens to people who switch
Lab chemistry is one thing; lungs are another. The user data points the same way.
A large internet survey published in the Harm Reduction Journal in 2007 (Barnwell & Earleywine) found that vaporiser users reported significantly fewer respiratory symptoms than smokers, even after controlling for age, sex, cigarette use and the amount of cannabis consumed.
Notably, the protective effect grew larger the more cannabis someone used — exactly what you’d expect if combustion, not cannabis, is the main respiratory culprit.
A small follow-up trial by Van Dam and Earleywine took it further: cannabis smokers with existing respiratory symptoms switched to a vaporiser for a month, and showed meaningful improvements in both self-reported symptoms and lung function (forced vital capacity) in just 30 days. A 2015 review in the Canadian Journal of Respiratory Therapy reached the same conclusion: the initial literature consistently suggests vaporised cannabis carries lower respiratory risk than smoked.
Patients have noticed. In a survey of Canadian medical cannabis users, vaporisers had already overtaken joints as the most popular consumption method, with reduced health harm cited as the primary reason — and vaporiser users were again significantly less likely to report cough, phlegm and chest tightness.
The caveats nobody mentions
Now for the honest bit.
Vapour hits harder than you think. A 2018 crossover trial from Johns Hopkins, published in JAMA Network Open (Spindle et al.), gave infrequent users identical THC doses smoked and vaporised. The vaporised cannabis produced stronger effects and higher blood THC than the same dose smoked — including more anxiety and paranoia at the higher dose. Vaporisers are more efficient at delivering THC, because less of it is destroyed by the flame. If you switch, start lower than you think you need.
“Vaping” is two different things. The 2019 EVALI outbreak — the wave of severe lung injuries in the US — was overwhelmingly linked to illicit THC oil cartridges cut with vitamin E acetate, not to dry herb vaporisers heating actual flower. Conflating the two has muddied public understanding badly. A quality dry herb device from an established manufacturer, used with flower, is a fundamentally different proposition to a black-market distillate cart.
Safer isn’t safe. There are no 30-year cohort studies of dry herb vaporiser users, because the devices haven’t been mainstream for 30 years. Inhaling hot vapour of any kind is unlikely to be entirely benign. The evidence supports harm reduction, not harm elimination — and researchers reviewing the field, like this 2022 commentary, are careful to frame it exactly that way.
The practical takeaway
If you consume cannabis by inhalation and you’re going to keep doing so, the research points clearly in one direction: taking the fire out of the equation removes most of the compounds that cause the coughing, the phlegm and the long-term respiratory grief, while delivering the cannabinoids just as effectively — arguably more so.
The barrier used to be cost and clunkiness, and honestly, neither argument holds up anymore. Battery-free devices like the DynaVap start at pocket-money prices, and even the German-engineered flagships from Storz & Bickel have come down to earth; UK specialists such as vaporiser.co.uk now carry the full spread, from manual glass vapes to desktop units, which tells you how far this corner of the market has matured.
Whatever you buy, the advice from the pharmacology is the same: start at a lower temperature and a smaller dose than your smoker’s instincts suggest, and work up slowly.
Twenty years ago, vaporizers were a curiosity that appeared in the occasional academic photograph. Today they’re the single most evidence-backed harm reduction step an inhaling cannabis user can take. That’s not hype — it’s what the research actually says.
References
- Wu TC, Tashkin DP, et al. Pulmonary hazards of smoking cannabis as compared with tobacco. N Engl J Med. 1988. doi.org/10.1056/NEJM198802113180603
- Moir D, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke. Chem Res Toxicol. 2008. (Findings summarised in Graves et al., Sci Rep 2020)
- Abrams DI, et al. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther. 2007. PubMed
- Barnwell S, Earleywine M. Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct J. 2007. Full text
- Loflin M, Earleywine M. No smoke, no fire: what the initial literature suggests regarding vapourized cannabis and respiratory risk. Can J Respir Ther. 2015. Full text
- Shiplo S, et al. Medical cannabis use in Canada: vapourization and modes of delivery. Harm Reduct J. 2016. Full text
- Spindle TR, et al. Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial. JAMA Netw Open. 2018. Full text
- Chaiton M, et al. Vaping cannabis: harm reduction or harm production? Commentary. 2022. Full text
Related reading: The Quiet Revolution of CBD: What We Actually Know · BC Bud Was Always Special. Legalization Just Made It Officia
